- Home
- PRME vs URGN Comparison
PRME vs URGN Comparison
Compare PRME & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- URGN
- Stock Information
- Founded
- PRME 2019
- URGN 2004
- Country
- PRME United States
- URGN United States
- Employees
- PRME N/A
- URGN N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- URGN Health Care
- Exchange
- PRME Nasdaq
- URGN Nasdaq
- Market Cap
- PRME 165.4M
- URGN 181.2M
- IPO Year
- PRME 2022
- URGN 2017
- Fundamental
- Price
- PRME $1.67
- URGN $7.02
- Analyst Decision
- PRME Buy
- URGN Strong Buy
- Analyst Count
- PRME 6
- URGN 8
- Target Price
- PRME $9.38
- URGN $22.92
- AVG Volume (30 Days)
- PRME 2.7M
- URGN 4.0M
- Earning Date
- PRME 05-08-2025
- URGN 05-12-2025
- Dividend Yield
- PRME N/A
- URGN N/A
- EPS Growth
- PRME N/A
- URGN N/A
- EPS
- PRME N/A
- URGN N/A
- Revenue
- PRME $3,846,000.00
- URGN $91,871,000.00
- Revenue This Year
- PRME $104.12
- URGN $30.00
- Revenue Next Year
- PRME $196.78
- URGN $102.76
- P/E Ratio
- PRME N/A
- URGN N/A
- Revenue Growth
- PRME 550.76
- URGN 8.98
- 52 Week Low
- PRME $1.11
- URGN $3.42
- 52 Week High
- PRME $8.14
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- PRME 61.84
- URGN 50.56
- Support Level
- PRME $1.20
- URGN $4.80
- Resistance Level
- PRME $1.35
- URGN $8.25
- Average True Range (ATR)
- PRME 0.13
- URGN 0.73
- MACD
- PRME 0.06
- URGN 0.33
- Stochastic Oscillator
- PRME 79.43
- URGN 70.73
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.